Category: T2 Biosystems Inc.Syndicate content

T2 Biosystems prepares to go public in an offering that could garner $69 million | Medtech Wall Street news for the week of July 7, 2014

July 10, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: T2 Biosystems prepares $69M IPO for MRI-based diagnostics; Philips Healthcare retools, CEO DiSanzo is out; iRadimed sets terms for $10M IPO

T2 Biosystems prepares $69M IPO for MRI-based diagnostics

July 2, 2014 by Arezu Sarvestani

T2 Biosystems prepares to go IPO

T2 Biosystems prepares $69M IPO for MRI-based diagnostics

July 2, 2014 by Arezu Sarvestani

Massachusetts-based T2 Biosystems registers for an initial public offering worth up to $69 million in support of its novel magnetic resonance imaging-based diagnostic systems.

T2 Biosystems prepares to go IPO

Diagnostics-maker   is preparing to go public in an offering that could garner as much as $69 million, according to SEC filings.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Orthofix names interim CFO, taps CareFusion CFO for board | Personnel Moves

April 28, 2014 by Brad Perriello

Orthofix names David Ziegler as interim CFO after Emily Buxton's resignation and names CareFusion CFO James Hinrichs to its board of directors.

Orthofix names interim CFO, taps CareFusion CFO for board | Personnel Moves

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Imaging3 names new CEO | Personnel Moves

December 16, 2013 by Chris Walker

Imaging3 names Dane Medley as its new CEO, replacing the outgoing Dean James in the corner office.

fired/hired

Imaging3 (OTC:IMGG) said Dane Medley will replace Dean James as chairman & CEO.

Medley's résumé includes time with Xerox (NYSE:XRX) and Sharp Electronics. Medley also started 360 Dynamic Technology, a privately owned startup that provides sales and service for office products/technology.

T2 Biosystems launches sepsis trial

September 11, 2013 by Brad Perriello

T2 Biosystems launches a clinical trial of its T2Candida test to detect Candida, a leading cause of hospital-acquired infections that can lead to deadly cases of sepsis.

T2 Biosystems launches sepsis trial

T2 Biosystems said it's launched a clinical trial of its MR-based test for a fungus that's a common cause of deadly hospital-acquired infections.

The Lexington, Mass.-based company said it plans to use the study results to back a regulatory submission for the T2Candida test for the Candida fungus, estimated to cause some 100,000 cases of candidemia each year in the U.S.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

T2 Biosystems aims to revolutionize diagnostics

July 22, 2013 by Brad Perriello

T2 Biosystems CEO John McDonough tells MassDevice.com why the medical device company's MRI-based diagnostics tool could revolutionize diagnostics and save millions of lives in the process.

T2 Biosystems CEO John McDonough

When MassDevice.com last spoke with T2 Biosystems CEO John McDonough, in August 2009, the 22-worker firm was still developing a novel use for MRI technology – diagnostics.

T2's device uses magnetic resonance to identify pathogens in just about any kind of sample, eliminating the need for time-consuming blood culture work.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp